Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Blood

Volumn 118, Issue 8, 2011, Pages 2333-2341

  Østergaard, Henrik ^a   Bjelke, Jais R ^a   Hansen, Lene ^a   Petersen, Lars Christian ^a   Pedersen, Anette A ^a   Elm, Torben ^a   Møller, Flemming ^a   Hermit, Mette B ^a   Holm, Pernille K ^a   Krogh, Thomas N ^a   Petersen, Jørn M ^a   Ezban, Mirella ^a   Sørensen, Brit B ^a   Andersen, Mette D ^a   Agersø, Henrik ^a   Ahmadian, Haleh ^a   Balling, Kristoffer W ^a   Christiansen, Marie Louise S ^a   Knobe, Karin ^b   Nichols, Timothy C ^c   Bjørn, Søren E ^a   Tranholm, Mikael ^a   more..

^a NOVO NORDISK A S   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDASE; MACROGOL; PEPTIDE; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOG; DRUG HALF LIFE; ENZYME ACTIVATION; ENZYME METABOLISM; HEMOPHILIA B; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SWINE;

EID: 80052167452     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-336172     Document Type: Article

References (46)

1. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53(4):505-518.
2. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982;79(21):6461-6464. (Pubitemid 13207514)
3. Makino Y, Omichi K, Kuraya N, et al. Structural analysis of N-linked sugar chains of human blood clotting factor IX. J Biochem. 2000;128(2):175-180.
4. van DG, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256(7):3433-3442. (Pubitemid 11077003)
5. Giangrande PL, Black C. World Federation of Haemophilia programs in developing countries. Semin Thromb Hemost. 2005;31(5):555-560. (Pubitemid 41642569)
6. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol. 1998;35(2 suppl 2):33-38. (Pubitemid 28177999)
7. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7(2):133-139. (Pubitemid 32243794)
8. Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13(3):233-243. (Pubitemid 46746045)
9. National Hemophilia Foundation. MASAC Recommendation #179 Concerning Prophylaxis.Available at http://www.hemophilia.org/NHFWeb/MainPgs/ MainNHF.aspx?menuid=57&contentid=1007. Accessed February 10, 2011.
10. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator- prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia. 2010;16(3):460-468.
11. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia. 2004;10(suppl 4):97-104. (Pubitemid 40045427)
12. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102(4):634-644.
13. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270-279.
14. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-2064.
15. Begbie ME, Mamdani A, Gataiance S, et al. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thromb Haemost. 2005;94(6):1138-1147. (Pubitemid 41819607)
16. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006; 13(6):399-409. (Pubitemid 44470219)
17. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167-4183.
18. Christiansen ML, Balling KW, Persson E, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia. 2010;16(6):878-887.
19. Cheung WF, Straight DL, Smith KJ, Lin SW, Roberts HR, Stafford DW. The role of the epidermal growth factor-1 and hydrophobic stack domains of human factor IX in binding to endothelial cells. J Biol Chem. 1991;266(14):8797-8800. (Pubitemid 21906585)
20. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
21. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997; 90(10):3962-3966. (Pubitemid 27484049)
22. Nichols TC, Dillow AM, Franck HW, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency. ILAR J. 2009;50(2):144-167.
23. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Røjkjær R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102(10):3615-3620. (Pubitemid 37409379)
24. Møller F, Tranholm M. A ferric chloride induced arterial injury model used as haemostatic effect model. Haemophilia. 2010;16(1):e216-e222.
25. Xu L, Mei M, Haskins ME, et al. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res. 2007;120(2):269-280. (Pubitemid 46754415)
26. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem. 1986;261(21):9622-9628. (Pubitemid 17214084)
27. Harrison S, Adamson S, Bonam D, et al. The manufacturing process for recombinant factor IX. Semin Hematol. 1998;35(2 Suppl 2):4-10. (Pubitemid 28177994)
28. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol. 1998;35(2 suppl 2):11-17. (Pubitemid 28177995)
29. Gillis S, Furie BC, Furie B, et al. gamma-carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci. 1997;6(1):185-196. (Pubitemid 27045258)
30. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78(1):261-265. (Pubitemid 27289251)
31. Agarwala KL, Kawabata S, Takao T, et al. Activation peptide of human factor IX has oligosaccharides Oglycosidically linked to threonine residues at 159 and 169. Biochemistry. 1994;33(17):5167-5171. (Pubitemid 24150983)
32. Sturzebecher J, Kopetzki E, Bode W, Hopfner KP. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. FEBS Lett. 1997;412(2):295-300. (Pubitemid 27321269)
33. Cheung WF, van den BJ, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A. 1996;93(20):11068-11073. (Pubitemid 26333119)
34. Cheung WF, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem. 1992;267(29):20529-20531.
35. Viuff D, Andersen S, Sorensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res. 2010;126(2):144-149.
36. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3):214-221. (Pubitemid 37361666)
37. Fuchs HE, Trapp HG, Griffith MJ, Roberts HR, Pizzo SV. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest. 1984;73(6):1696-1703. (Pubitemid 14084486)
38. Kirchhofer D, Lipari MT, Moran P, Eigenbrot C, Kelley RF. The tissue factor region that interacts with substrates factor IX and Factor X. Biochemistry. 2000;39(25):7380-7387. (Pubitemid 30422054)
39. Sinha D, Marcinkiewicz M, Navaneetham D, Walsh PN. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation. Biochemistry. 2007;46(34):9830-9839. (Pubitemid 47328589)
40. Tranholm M, Kjalke M, Tornehave D, Sørensen BB, Kristensen AT, Røjkjær R. Recombinant FVIIa acts in a tissue factor independent way in a mouse model of hemophilia A. J Thromb Haemost. 2005;3(suppl 1):P0748.
41. Gui T, Lin HF, Jin DY, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood. 2002; 100(1):153-158. (Pubitemid 35177441)
42. Brinkhous KM, Sigman JL, Read MS, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood. 1996;88(7):2603-2610. (Pubitemid 26327511)
43. Atoda H, Yokota E, Morita T. Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX. J Biol Chem. 2006;281(14):9314-9320. (Pubitemid 43864647)
44. Chang J-Y, Brock J, Griffith MJ, Monroe DM. Glycosylation of the activation peptide of factor IX determines plasma half-life [abstract]. J Thromb Haemost. 2007;5(suppl 2):Abstract O-M-088.
45. Griffith MJ, Monroe DM, Van Cott KE, Walker A, Waugh S, Drohan WN. N-glycan sialylation is important for in vivo recovery of recombinant factor IX. J Thromb Haemost. 2007;5(suppl 2):Abstract P-M-043.
46. Gui T, Reheman A, Ni H, et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost. 2009;7(11):1843-1851.